[go: up one dir, main page]

ZA200503654B - Fused heterocyclic compounds - Google Patents

Fused heterocyclic compounds Download PDF

Info

Publication number
ZA200503654B
ZA200503654B ZA200503654A ZA200503654A ZA200503654B ZA 200503654 B ZA200503654 B ZA 200503654B ZA 200503654 A ZA200503654 A ZA 200503654A ZA 200503654 A ZA200503654 A ZA 200503654A ZA 200503654 B ZA200503654 B ZA 200503654B
Authority
ZA
South Africa
Prior art keywords
compound
alkyl
group
mmol
aryl
Prior art date
Application number
ZA200503654A
Other languages
English (en)
Inventor
Xi Chen
Xiaoqi Chen
Pingchen Fan
Juan Jaen
Leping Li
Jeffrey T Mihalic
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ZA200503654B publication Critical patent/ZA200503654B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200503654A 2002-11-06 2003-11-06 Fused heterocyclic compounds ZA200503654B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42445602P 2002-11-06 2002-11-06

Publications (1)

Publication Number Publication Date
ZA200503654B true ZA200503654B (en) 2006-09-27

Family

ID=32312811

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200503654A ZA200503654B (en) 2002-11-06 2003-11-06 Fused heterocyclic compounds

Country Status (16)

Country Link
US (2) US7253179B2 (fr)
EP (1) EP1562943A1 (fr)
JP (1) JP4547266B2 (fr)
KR (1) KR20050103184A (fr)
CN (2) CN1330651C (fr)
AU (1) AU2003285160B2 (fr)
BR (1) BR0316070A (fr)
CA (1) CA2505372A1 (fr)
EA (1) EA009421B1 (fr)
IS (1) IS7833A (fr)
MX (1) MXPA05004739A (fr)
NO (1) NO20052655L (fr)
NZ (1) NZ540328A (fr)
PL (1) PL376659A1 (fr)
WO (1) WO2004043958A1 (fr)
ZA (1) ZA200503654B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809104B2 (en) * 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US20070135425A1 (en) * 2001-05-04 2007-06-14 Amgen Inc. Fused heterocyclic compounds
JP4547266B2 (ja) 2002-11-06 2010-09-22 アムジエン・インコーポレーテツド 縮合複素環化合物
CA2515717A1 (fr) 2003-02-10 2004-08-19 Banyu Pharmaceutical Co., Ltd. Antagonistes des recepteurs de l'hormone concentrant la melanine contenant des derives de piperidine en tant que principe actif
DE102010025663A1 (de) * 2010-06-30 2012-01-05 Karl-Heinz Glüsenkamp Neue beta-Aminoaldehyd-Derivate, Verfahren zu ihrer Herstellung und ihre chemische Verwendung als reaktive Intermediate
MX2013001612A (es) * 2010-08-10 2013-07-05 Abbvie Inc Moduladores de trpv3 novedosos.
WO2012129491A1 (fr) 2011-03-24 2012-09-27 Abbott Laboratories Modulateurs de trpv3
EP2771322A2 (fr) * 2011-10-24 2014-09-03 AbbVie Inc. Nouveaux modulateurs de trpv3
CN106588812B (zh) * 2016-12-07 2019-02-22 烟台大学 一种酰氯制备2，4-二取代噻唑啉类化合物的方法
US12084416B2 (en) * 2019-01-14 2024-09-10 Zydus Lifesciences Limited Substituted sulfonylurea derivatives
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US176694A (en) * 1876-04-25 Improvement in screw-cutting die-stocks
US23085A (en) * 1859-03-01 chandler
US199549A (en) * 1878-01-22 Improvement in screw-propellers
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
JPS63258474A (ja) 1986-08-15 1988-10-25 セドナ・ファ−マセウチカルズ・ビ−・ブイ カルバゾ−ル、ジベンゾフラン又はジベンゾチオフェン基を含む化合物の水酸基誘導体を調製するための方法
US5049655A (en) 1989-03-22 1991-09-17 The Salk Institute For Biological Studies Melanin-concentrating hormones
JP2906654B2 (ja) 1989-11-28 1999-06-21 東レ株式会社 免疫抑制剤及びその製造方法
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
JP3160941B2 (ja) 1991-06-17 2001-04-25 東レ株式会社 カルバゾール誘導体および免疫抑制剤
JP3253077B2 (ja) 1991-07-05 2002-02-04 スミスクライン・ビーチャム・ファーマシューティチ・ソシエタ・ペル・アチオニ ヒドロイソキノリン誘導体
CA2124455C (fr) 1992-09-29 2004-09-14 Hiroshi Nagase Derives indole, methode de production et utilisation en medecine
US5272146A (en) 1992-10-02 1993-12-21 The United States Of America As Represented By The United States Department Of Health And Human Services 1,2-dihydroellipticines with activity against CNS specific cancer cell lines
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US5849708A (en) 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
EP0848060A3 (fr) 1996-12-11 2000-02-02 Smithkline Beecham Corporation Variante d'épissure de 11CB humaine
NZ331769A (en) 1997-01-16 2000-05-26 Toray Industries Indolomorphinan derivative and agent for curing and preventing cerebral disorder
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
WO1999028492A1 (fr) 1997-12-03 1999-06-10 Smithkline Beecham Corporation Procede de recherche d'un agoniste ou d'un antagoniste du variant d'epissage de 11 cb humain
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
AU6035999A (en) 1998-09-17 2000-04-03 Incyte Pharmaceuticals, Inc. Human gpcr proteins
GB9822158D0 (en) 1998-10-09 1998-12-02 Nycomed Imaging As Compositions
ATE354098T1 (de) 1998-12-28 2007-03-15 Takeda Pharmaceutical Screening-verfahren
US6221613B1 (en) 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
WO2000049170A1 (fr) 1999-02-18 2000-08-24 Smithkline Beecham Corporation RECEPTEUR 11cby MURIN
EP1153932A1 (fr) 1999-02-19 2001-11-14 Takeda Chemical Industries, Ltd. Nouvelle proteine de recepteur couplee a la proteine g et adn
WO2000070347A1 (fr) 1999-05-19 2000-11-23 Astrazeneca Ab Dosages pour agonistes, antagonistes et agonistes inverses d'hormone concentrant la melanine (mch) se liant au recepteur du type somatostatine (slc-1)
AU5869100A (en) 1999-06-08 2000-12-28 Regents Of The University Of California, The Melanin concentrating hormone receptor
CA2378917A1 (fr) 1999-07-14 2001-01-25 Merck & Co., Inc. Recepteur d'hormone concentrant la melanine
EP1196570A2 (fr) 1999-07-26 2002-04-17 Genentech, Inc. Polynucleotides et technique d'utilisation de ceux-ci
WO2001007606A1 (fr) 1999-07-27 2001-02-01 Smithkline Beecham Plc Axor21, recepteur couple g-proteine
AU7315800A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Mch antagonists
EP1218336A2 (fr) 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
EP1233981A4 (fr) 1999-11-16 2003-02-12 Merck & Co Inc Recepteur couple a la proteine g
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
WO2001068706A1 (fr) 2000-03-15 2001-09-20 Merck & Co., Inc. Proteines chimeres et de fusion du recepteur de l'hormone de concentration de la melanine
JP2005229804A (ja) 2000-03-24 2005-09-02 Astellas Pharma Inc 新規なメラニンコンセントレーティングホルモン受容体
EP1283199A4 (fr) 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd Antagoniste de l'hormone de concentration de la melanine
CA2384041A1 (fr) 2000-07-05 2002-01-24 Synaptic Pharmaceuticals Corporation Antagonistes selectifs des recepteurs (mch1) d'hormone-1 de concentration de la melanine et utilisation de ceux-ci
JP2004502423A (ja) 2000-07-05 2004-01-29 シナプティック・ファーマスーティカル・コーポレーション ヒトメラニン濃縮ホルモン受容体（ｍｃｈ１）をコードするｄｎａ及びその使用
ATE489626T1 (de) 2000-07-05 2010-12-15 Takeda Pharmaceutical Verfahren zum screenen von mhc- rezeptorantagonisten oder -agonisten
EP1366030A2 (fr) * 2000-07-06 2003-12-03 Neurogen Corporation Ligands de recepteur d'hormone a concentration de melanine
AP2001002307A0 (en) 2000-10-20 2001-12-31 Pfizer Prod Inc B3 adrenergic receptor agonists and uses thereof.
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
DE60112791T2 (de) * 2000-12-22 2006-06-08 Schering Corp. Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität
CA2441235C (fr) 2001-03-21 2011-05-24 Pharmacopeia, Inc. Composes d'aryle et de biaryle ayant une activite modulatrice de mch
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
JP4280073B2 (ja) 2001-04-12 2009-06-17 ファーマコペイア ドラッグ ディスカバリー， インコーポレイテッド Ｍｃｈアンタゴニストとして使用されるアリールピペリジンおよびビアリールピペリジン
AU2002305323A1 (en) 2001-05-04 2002-11-18 Tularik Inc. Fused heterocyclic compounds
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
JP2005515961A (ja) 2001-05-22 2005-06-02 ニューロジェン コーポレイション メラニン凝集ホルモン受容体リガンド：置換１−ベンジル−４−アリールピペラジン類似体
JP2005510563A (ja) * 2001-11-26 2005-04-21 シェーリング　コーポレイション 肥満およびｃｎｓ障害の処置のためのピペリジン系ｍｃｈアンタゴニスト
EP1465635A4 (fr) * 2002-01-10 2005-04-13 Neurogen Corp Ligands recepteurs de l'hormone de concentration de la melanine: 2-(4-benzyl-piperazine-1-ylmethyl)- substitue et analogues de 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole
JP4547266B2 (ja) * 2002-11-06 2010-09-22 アムジエン・インコーポレーテツド 縮合複素環化合物

Also Published As

Publication number Publication date
JP2006508130A (ja) 2006-03-09
WO2004043958A1 (fr) 2004-05-27
CN1330651C (zh) 2007-08-08
CN1735613A (zh) 2006-02-15
US20040147538A1 (en) 2004-07-29
NO20052655L (no) 2005-07-26
NZ540328A (en) 2008-02-29
EP1562943A1 (fr) 2005-08-17
MXPA05004739A (es) 2005-08-02
CA2505372A1 (fr) 2004-05-27
KR20050103184A (ko) 2005-10-27
US7253179B2 (en) 2007-08-07
PL376659A1 (pl) 2006-01-09
AU2003285160A1 (en) 2004-06-03
EA009421B1 (ru) 2007-12-28
NO20052655D0 (no) 2005-06-02
EA200500770A1 (ru) 2005-12-29
BR0316070A (pt) 2005-09-27
AU2003285160B2 (en) 2009-06-04
US20080058365A1 (en) 2008-03-06
IS7833A (is) 2005-05-02
JP4547266B2 (ja) 2010-09-22
CN101134757A (zh) 2008-03-05

Similar Documents

Publication Publication Date Title
US20080058365A1 (en) Fused heterocyclic compounds
US7045527B2 (en) Piperidine derivatives
EP1392298B1 (fr) Composes heterocycliques fondus
CN106661002B (zh) 用于治疗炎性、代谢性、肿瘤性和自身免疫性疾病的嘧啶衍生物
AU2007249925A1 (en) Substituted azaspiro derivatives
CA2611296A1 (fr) Derives de pyrazolopyridine utilises en tant qu'inhibiteurs de la kinase 1 du recepteur $g(b)-adrenergique
EP4305029A1 (fr) Nouveaux dérivés de 2,3-dihydro-1h-pyrrolo[3,2-b]pyridine utiles en tant que ligands sigma
KR20240013134A (ko) 시그마 리간드로서 피리딘-술폰아미드 유도체
US6809104B2 (en) Fused heterocyclic compounds
JP2018533598A (ja) 薬物乱用の治療および薬物中毒の治療のためのオキサ−アザスピロ化合物
JP2006526021A (ja) 肥満およびｃｎｓ障害を治療する選択的ｄ１／ｄ５レセプタアンタゴニストとしての５ｈ−ベンゾ［ｄ］ナフト［２，１−ｂ］アゼピン誘導体
BR112020018767A2 (pt) inibidores de secreção de proteínas à base de triazaciclododecansulfonamida (tcd)
US20070135425A1 (en) Fused heterocyclic compounds